PI3K Cancer Research Results

PI3K, Phosphatidylinositide-3-Kinases: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS
Type:
Phosphatidylinositol 3-kinase (PtdIns3K or PI3K) is a family of enzymes that play a crucial role in cell signaling pathways, particularly in the regulation of cell growth, survival, and metabolism. The PI3K pathway is one of the most frequently altered pathways in human cancer. Inhibition of the PI3K pathway has been explored as a therapeutic strategy for cancer treatment. Several PI3K inhibitors have been developed and are currently being tested in clinical trials. These inhibitors can target specific components of the pathway, such as PI3K, AKT, or mTOR.

Class I phosphoinositide 3-kinase (PI3K)
Class III PtdIns3K
In contrast to the class III PtdIns3K as a positive regulator of autophagy, class I PI3K-AKT signaling has an opposing effect on the initiation of autophagy.

PI3K inhibitors include:
-Idelalisib , Copanlisib, Alpelisib
-LY294002?
-Wortmannin: potent PI3K inhibitor, has some associated toxicity.
-Quercetin:
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
NSCLC, Non-small Cell Lung Cancer: Click to Expand ⟱
Non-small Cell Lung Cancer
Scientific Papers found: Click to Expand⟱
6399- ANE,    Anethole attenuates lung cancer progression by regulating the proliferation and apoptosis through AKT and STAT3 signaling
- vitro+vivo, NSCLC, A549
TumCP↓, TumCG↓, Apoptosis↑, DNAdam↑, Casp3↑, PI3K↓, Akt↓, STAT3↓, Ki-67↓, cl‑Casp3↑,
5540- BBM,    Berbamine Inhibits Cell Proliferation and Migration and Induces Cell Death of Lung Cancer Cells via Regulating c-Maf, PI3K/Akt, and MDM2-P53 Pathways
- vitro+vivo, NSCLC, NA
TumCMig↓, TumCI↓, PI3K↓, Akt↓, MDM2↓, TumCP↓, TumMeta↓,
5180- BBR,    Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth
- in-vitro, NSCLC, NA
TumCMig↓, TumCP↓, Apoptosis↑, TFAP2A↓, hTERT/TERT↓, NF-kB↓, COX2↓, Hif1a↓, VEGF↓, Akt↓, p‑ERK↓, Cyt‑c↑, cl‑Casp↑, cl‑PARP↑, PI3K↓, Akt↓, Raf↓, MEK↓, ERK↓,
6548- BSB,    Anticancer effects of α-Bisabolol in human non-small cell lung carcinoma cells are mediated via apoptosis induction, cell cycle arrest, inhibition of cell migration and invasion and upregulation of P13K/AKT signalling pathway
- in-vitro, NSCLC, A549
AntiCan↑, Dose↝, TumCCA↑, mt-Apoptosis↑, TumCMig↓, PI3K↓, Akt↓,
6677- Deg,    Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis
- in-vitro, NSCLC, NA
Glycolysis↓, TumCG↓, Akt↓, Apoptosis↑, TumCP↓, HK2↓, PI3K↓, cMyc↓,
4920- PEITC,  Cisplatin,    PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p
- vitro+vivo, NSCLC, A549
TumCG↓, ChemoSen↑, cMyc↓, PI3K↓, Akt↓, mTOR↓, BioAv↝, tumCV↓, ChemoSen↑,
4662- RES,    A Promising Resveratrol Analogue Suppresses CSCs in Non-Small-Cell Lung Cancer via Inhibition of the ErbB2 Signaling Pathway
- in-vitro, NSCLC, A549 - in-vitro, NSCLC, H460
CSCs↓, CD133↓, OCT4↓, β-catenin/ZEB1↓, HER2/EBBR2↓, TumCP↓, PI3K↓, Akt↓, ALDH1A1↓, eff↑,
5103- SK,    Attenuation of PI3K-Akt-mTOR Pathway to Reduce Cancer Stemness on Chemoresistant Lung Cancer Cells by Shikonin and Synergy with BEZ235 Inhibitor
- in-vitro, NSCLC, A549
CSCs↓, TumCP↓, Nanog↓, OCT4↓, p‑Akt↓, P70S6K↓, PI3K↓, mTOR↓, eff↑,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


Mitochondria & Bioenergetics(tgid=3) ⓘ

MEK↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 2,   Glycolysis↓, 1,   HK2↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 8,   p‑Akt↓, 1,   Apoptosis↑, 3,   mt-Apoptosis↑, 1,   cl‑Casp↑, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Cyt‑c↑, 1,   hTERT/TERT↓, 1,   MDM2↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TFAP2A↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CD133↓, 1,   CSCs↓, 2,   ERK↓, 1,   p‑ERK↓, 1,   mTOR↓, 2,   Nanog↓, 1,   OCT4↓, 2,   P70S6K↓, 1,   PI3K↓, 8,   STAT3↓, 1,   TumCG↓, 3,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   TumCI↓, 1,   TumCMig↓, 3,   TumCP↓, 6,   TumMeta↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 2,   Dose↝, 1,   eff↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,  
Total Targets: 51

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PI3K, Phosphatidylinositide-3-Kinases
1 Anethole/trans-Anethole
1 Berbamine
1 Berberine
1 α-Bisabolol / Chamomile oil
1 Deguelin
1 Phenethyl isothiocyanate
1 Cisplatin
1 Resveratrol
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:19  Cells:%  prod#:%  Target#:252  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page